Table 1 Baseline characteristics of patients
Baseline Characteristics | All n = 5991 (%) | ID n = 275 (45.9%) | Non-ID n = 324 (54.1%) | P-value |
|---|---|---|---|---|
Age (mean ± SD, range) | 60.4 ± 15.3 (16–93) | 61.5 ± 15.2 (16–88) | 59.4 ± 15.4 (18–93) | p = 0.089 |
Sex | p = 0.038 | |||
Female | 363 (60.6%) | 179 (65.1%) | 184 (56.8%) | |
Type of visit | p = 0.085 | |||
Pre-surgery/pre-chemotherapy | 239 (39.9%) | 122 (44.4%) | 117 (36.1%) | |
Current cancer treatment | 243 (40.6%) | 107 (38.9%) | 136 (42.0%) | |
Post-treatment | 117 (19.5%) | 46 (16.7%) | 71 (21.9%) | |
Cancer location | p = 0.101 | |||
Breast | 181 (30.2%) | 86 (31.3%) | 95 (29.3%) | |
Genitourinary | 80 (13.4%) | 32 (11.6%) | 48 (14.8%) | |
Sarcoma | 67 (11.2%) | 29 (10.5%) | 38 (11.7%) | |
Gastrointestinal | 63 (10.5%) | 33 (12.0%) | 30 (9.3%) | |
Thyroid | 53 (8.8%) | 25 (9.1%) | 28 (8.6%) | |
Gynecologic | 50 (8.3%) | 26 (9.5%) | 24 (7.4%) | |
Hematologic | 41 (6.8%) | 12 (4.4%) | 29 (9.0%) | |
Others | 34 (5.7%) | 12 (4.4%) | 22 (6.8%) | |
Melanoma | 18 (3.0%) | 12 (4.4%) | 6 (1.9%) | |
Lung | 12 (2.0%) | 8 (2.9%) | 4 (1.2%) | |
Previous cancer history | 39 (6.5%) | 19 (6.9%) | 20 (6.2%) | p = 0.716 |
Cardiovascular risk factors | ||||
Hypertension | 224 (37.5%) | 110 (40%) | 114 (35.2%) | p = 0.225 |
Diabetes | 67 (11.2%) | 42 (15.3%) | 25 (7.7%) | p = 0.003 |
Dyslipidaemia | 79 (13.2%) | 31 (11.3%) | 48 (14.8%) | p = 0.202 |
Previous HF | 20 (3.3%) | 11 (4.0%) | 9 (2.8%) | |
Prior CAD | 55 (9.1%) | 28 (10.2%) | 27 (8.3%) | |
Valvular Heart Disease | 17 (2.8%) | 9 (3.3%) | 8 (2.5%) | |
Smoking | 47 (7.8%) | 21 (7.6%) | 26 (8%) | p = 0.966 |
Elevated BNP | 463 (77.3%) | 218 (79.3%) | 245 (75.6%) | p = 0.523 |
LVEF (mean ± SD, range, %) | 57.5 ± 11.0 (20–85) | 57.7 ± 10.6 (21–80) | 57.4 ± 11.3 (20–85) | p = 0.750 |
LVEF< 50% | 107 (17.9%)2 | 46 (16.7%) | 61 (18.8%) | p = 0.504 |
Kidney dysfunction | p = 0.006 | |||
GFR < 60 ml/min/1.73 m2 | 119 (19.9%) | 68 (24.7%) | 51 (15.7%) | |
TSAT (mean ± SD, range, %) | 23 ± 14.1 (3.0–99.0) | 13.6 ± 14.1 (3.0–19.0) | 30.9 ± 14.7 (20.0–99.0) | p < 0.001 |
Median | 20 | 14 | 26 | |
Ferritin (μg/L, mean ± SD, range) | 188.0 ± 297.9 (6.0–1500.0) | 125.7 ± 201.9 (6.0–1500.0) | 241.2 ± 351.8 (11.0–1500.0) | p < 0.001 |
Ferritin < 100 μg/L | 343 (57.3%) | 186 (67.6%) | 157 (48.4%) | |
Ferritin ≥ 100 μg/L | 252 (42.1%) | 88 (32.0%) | 164 (50.6%) | |
Serum iron (umol/L, mean ± SD, range) | 14.3 ± 7.9 (1.6–76) | 9.2 ± 5.1 (1.6–76) | 18.6 ± 7.2 (8.6–61.0) | p < 0.001 |
Iron < 12 umol/L | 253 (42.2%)3 | 229 (83.3%) | 24 (7.4%) | |
Anemia | 244 (40.7%) | 144 (52.4%) | 100 (30.9%) | p < 0.001 |
Normocytic | 164 (27.4%) | 93 (33.8%) | 71 (21.9%) | |
Microcytic | 56 (9.4%) | 47 (17.1%) | 9 (2.8%) | |
Macrocytic | 24 (4%) | 4 (1.4%) | 20 (6.2%) | |
Deceased during study period | 159 (26.5%) | 89 (32.4%) | 70 (21.6%) | p = 0.003 |